Leuprolide

Generic Name
Leuprolide
Brand Names
Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
Drug Type
Small Molecule
Chemical Formula
C59H84N16O12
CAS Number
53714-56-0
Unique Ingredient Identifier
EFY6W0M8TG
Background

Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...

Indication

Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.

It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...

Associated Conditions
Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Phase 3
Active, not recruiting
Conditions
Metastases
Interventions
Drug: Leuprorelin Acetate
First Posted Date
2011-09-28
Last Posted Date
2023-06-22
Lead Sponsor
UNICANCER
Target Recruit Count
700
Registration Number
NCT01442246
Locations
🇫🇷

Chu Bordeaux- Hopital Pellegrin, Bordeaux, France

🇫🇷

Clinique Victor Pauchet, Amiens, France

🇫🇷

Chu Besancon, Besancon, France

and more 32 locations

A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs

Not Applicable
Conditions
Implantation, Embryo
Interventions
Drug: Leuprolide
Drug: Ganirelix
First Posted Date
2011-08-29
Last Posted Date
2011-08-29
Lead Sponsor
Kelly, Maureen, M.D.
Target Recruit Count
20
Registration Number
NCT01424618
Locations
🇺🇸

Society Hill Reproductive Medicine, Philadelphia, Pennsylvania, United States

Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

Early Phase 1
Withdrawn
Conditions
Obesity
Polycystic Ovary Syndrome
Hyperandrogenemia
Interventions
Drug: Leuprolide
First Posted Date
2011-08-23
Last Posted Date
2018-07-19
Lead Sponsor
University of Virginia
Registration Number
NCT01422096
Locations
🇺🇸

University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

First Posted Date
2011-06-21
Last Posted Date
2023-09-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT01377389
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Preservation of Ovarian Function After Hematopoietic Cell Transplant

First Posted Date
2011-04-28
Last Posted Date
2017-12-05
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
19
Registration Number
NCT01343368
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

First Posted Date
2011-04-20
Last Posted Date
2021-03-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
76
Registration Number
NCT01338987
Locations
🇺🇸

Childrens National Medical Center, Washington, District of Columbia, United States

🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

🇺🇸

University of Oklahoma, Oklahoma City, Oklahoma, United States

GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.

Not Applicable
Completed
Conditions
Endometriosis
Infertility
Interventions
Drug: Leuprolide
Procedure: IVF
First Posted Date
2011-01-04
Last Posted Date
2013-07-30
Lead Sponsor
University of Ioannina
Target Recruit Count
180
Registration Number
NCT01269125
Locations
🇬🇷

Dept. of Obstetrics & Gynecology, University Hospital, Ioannina, Epirus, Greece

Influence of Male Hormones on Regional Fat Metabolism

Phase 1
Completed
Conditions
Obesity
Interventions
Drug: Leuprolide
Drug: Testosterone
First Posted Date
2010-07-12
Last Posted Date
2014-05-14
Lead Sponsor
Mayo Clinic
Target Recruit Count
39
Registration Number
NCT01160328
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448

First Posted Date
2010-05-28
Last Posted Date
2012-01-31
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT01132404
Locations
🇫🇷

Hôpital Edouard Herriot, 5, Place d'Arsonval, Pavillon V - Urologie et chirurgie de la transplantation, Lyon, France

Impact of Hot Flashes on Sleep and Mood Disturbance

Phase 4
Completed
Conditions
Menopause
Hot Flashes
Depression
Interventions
Drug: leuprolide
First Posted Date
2010-05-05
Last Posted Date
2018-01-23
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
29
Registration Number
NCT01116401
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy